Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.30 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.30 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.30 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636353 | 1.00 | HRH3 (0.32) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL16636152 | 0.86 | SLC6A12 (0.35) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL16635681 | 0.84 | KCNQ3 (0.33) | HRH3MAPK1CHRM2CHRM3MEN1 | |
| SCHEMBL16635680 | 0.84 | KCNQ3 (0.33) | HRH3MAPK1CHRM2CHRM3MEN1 | |
| SCHEMBL16635962 | 0.84 | CHRM2 (0.31) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL16635964 | 0.84 | CHRM2 (0.31) | HRH3MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL9450418 | 0.81 | KCNQ3 (0.33) | KCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL17008630 | 0.78 | CHRM2 (0.35) | CHRM2CHRM3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL18279798 | 0.78 | CHRM2 (0.35) | CHRM2CHRM3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL16635714 | 0.76 | SLC6A12 (0.40) | MEN1KMT2AKCNQ3KCNQ2KCNQ4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3054947-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-17 | — | — | EP | disclosed |
| US-9573913-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160244417-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3054947-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015054038-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244417-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | HRH3 1600/4885MAPK1 3353/4885CHRM2 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.